Physicochemical, Thermal, Structural, and Behavioral Properties Analysis in Magnesium Gluconate: An Effect of the Energy of Consciousness (The Trivedi Effect®)

Mahendra Kumar Trivedi1, Alice Branton1, Dahryn Trivedi1, Gopal Nayak1, Cathryn Dawn Nykvist1, Celine Lavelle1, Daniel Paul Przybylski1, Dianne Heather Vincent1, Dorothy Felger1, Douglas Jay Konersman1, Elizabeth Ann Feeney1, Jay Anthony Prague1, Joanne Lydia Starodub1, Karan Rasdan1, Karen Mic Strassman1, Leonid Soboleff1, Maire Anne Mayne1, Mary M. Keesece1, Padmanabha Narayana Pillai1, Pamela Clarkson Ansley1, Ronald David Schmitz1, Sharyn Marie Sodomora1, Kalyan Kumar Sethi2, Parthasarathi Panda2, Snehasis Jana2,*

1Trivedi Global, Inc., Henderson, Nevada, USA
2Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, Madhya Pradesh, India

Email address: publication@trivedieffect.com (S. Jana)
*Corresponding author

To cite this article:
Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Cathryn Dawn Nykvist, Celine Lavelle, Daniel Paul Przybylski, Dianne Heathcote Vincent, Dorothy Felger, Douglas Jay Konersman, Elizabeth Ann Feeney, Jay Anthony Prague, Joanne Lydia Starodub, Karan Rasdan, Karen Mic Strassman, Leonid Soboleff, Maire Anne Mayne, Mary M. Keesece, Padmanabha Narayana Pillai, Pamela Clarkson Ansley, Ronald David Schmitz, Sharyn Marie Sodomora, Kalyan Kumar Sethi, Parthasarathi Panda, Snehasis Jana. Physicochemical, Thermal, Structural, and Behavioral Properties Analysis in Magnesium Gluconate: An Effect of the Energy of Consciousness (The Trivedi Effect®). International Journal of Biomedical Materials Research. Vol. 5, No. 2, 2017, pp. 15-24. doi: 10.11648/j.ijbmr.20170502.11

Received: January 31, 2017; Accepted: February 23, 2017; Published: March 9, 2017

Abstract: Magnesium gluconate is an organometallic pharmaceutical/nutraceutical used for the prevention and treatment of various diseases caused by the low level of magnesium. The aim of the present study was to investigate the influence of The Trivedi Effect® - Energy of Consciousness Healing Treatment (Biofield Energy Healing) on the physicochemical, thermal, structural, and behavioral properties of magnesium gluconate using powder PXRD, PSD, FT-IR, UV-visible, TGA, and DSC analysis. Magnesium gluconate was divided into two parts - one part was denoted as the control, while the another part was treated with The Trivedi Effect® remotely by eighteen renowned Biofield Energy Healers and defined as the Trivedi Effect® Treated sample. The PXRD analysis exhibited the significant alteration of the crystal morphology of the treated sample compared with the control sample. The crystallite size of the treated sample was significantly altered from -39.99% to 62.57% compared with the control sample. The average crystallite size of the treated sample was decreased by 9.71% compared with the control sample. Particle size of the treated sample at d10, d50, and d90 value was significantly increased by 5.36%, 23.10% and 11.11%, respectively compared with the control sample. The surface area of the treated sample was significantly decreased by 9.76% compared to the control sample. The FT-IR and UV-vis analysis showed that the structural characteristic of the magnesium gluconate remained same in the treated sample compared with control sample. The TGA data revealed that the weight loss of the treated sample in the first and third steps of degradation was increased by 31.58% and 5.94%, respectively, whereas in the second step of degradation, the weight loss was decreased by 7.57% compared with the control sample. The DSC analysis showed that the melting point of the treated sample were at 170.29°C and 169.76°C, respectively. The latent heat of fusion of the treated sample was increased by 4.18% compared with the control sample. The current study evaluated that The Trivedi Effect® - Energy of Consciousness Healing Treatment might lead to a new polymorphic form of the magnesium gluconate, which could be more soluble, powder flowability and long-term storage stability compared with the control sample. Hence, the Trivedi Effect® Treated magnesium gluconate would be very useful to design better nutraceutical and/or pharmaceutical formulations that might provide better therapeutic response against inflammatory diseases,
1. Introduction

Magnesium ion (Mg$^{2+}$) is a major intracellular ion and plays an important role in the regulation of iRNA and rRNA structures. This ion is also a crucial cofactor for many RNA and DNA processing enzymes as well as for those enzymes using AMP, ADP, or ATP as substrates [1-3]. Hence, magnesium ion is an essential mineral element in human and animal nutrition. It is also used as a metallotherapeutic agent to treat many diseases such as asthma, arrhythmias, acute myocardial infarction, gestational hypertension, preeclampsia and eclampsia [1-8]. Perioperative magnesium supplementation is found to be very useful in the management of postoperative pain by inhibiting postoperative hypomagnesia as well as reducing the incidence of postoperative shivering [9, 10]. Gluconic acid is a minor organic acid formed from glucose through a simple dehydrogenation reaction catalyzed by the glucose oxidase. Gluconic acid and its derivatives are commonly used in the food and pharmaceutical industry [11]. Magnesium gluconate (MgC$_6$H$_{12}$O$_7$) is the magnesium salt of gluconic acid. It is used by itself or in combination with one or more antioxidants for the prevention and treatment of diabetes mellitus, allergies, septic shock, inflammatory diseases, immunological disorders, and other chronic infections [12, 13]. It can be used intravenously in the treatment of ischemia/reperfusion injury due to oxidative stress in order to block free radical flow [14]. This salt is used as an oral tocolytic agent in women, whose labor is arrested initially with intravenous therapy by acting on non-selective β-receptor [15]. The scientific literature reports that magnesium gluconate is the most powerful antioxidants than other magnesium salts [12]. Moreover, magnesium gluconate is physiologically acceptable salt among other salt forms [13]. Scientific literature mentions that the bioavailability of magnesium is less in humans, because they have difficulties in absorption of magnesium through the narrow channels in their biological membranes due to the higher steric constraints for magnesium transporters and incapability of its hydration shell [16, 17]. Magnesium gluconate showed the most magnesium absorption and highest bioavailability among the other form of magnesium salts such as chloride, sulfate, carbonate, acetate, citrate, lactate, aspartate, etc. [18].

In this point of view, a novel proprietary herbomineral formulation was designed as a nutraceutical supplement, and can be used for the prevention and treatment of various human disorders. Magnesium gluconate is one of the components in this novel proprietary herbomineral formulation as the source of magnesium ion.

Since ancient times, many different cultures, religions and systems of belief have recognized a living force that preserves and inhabits every living organism. This force is the source of ‘life’ and has been called various names, such as prana by the Hindus, qi or chi by the Chinese, and ki by the Japanese. This is believed to co-relate with the soul, spirit and mind. This hypothetical vital force has been scientifically evaluated and is now considered the Bioenergetics Field. The Biofield Energy is a dynamic electromagnetic field surrounding the human body, resulting from the continuous emission of low-level light, heat, and acoustical energy from the body. Biofield Energy is infinite, paradigmatical and can freely flow between the human and environment [19, 20]. So, a human has the ability to harness energy from the ionosphere of the earth, the “universal energy field”, and transmit it to any living organism(s) or nonliving object(s) around the globe. The object or recipient always receives the energy and responds in a useful way. This process is known as The Trivedi Effect® - Biofield Energy Healing Treatment [21]. Biofield (Putative Energy Field) based Energy Therapies are used worldwide to promote health and healing. The National Center of Complementary and Integrative Health (NCCIH) has recognized and accepted Biofield Energy Healing as a Complementary and Alternative Medicine (CAM) health care approach in addition to other therapies, medicines and practices such as natural products, deep breathing, yoga, Tai Chi, Qi Gong, chiropractic/osteopathic manipulation, meditation, massage, special diets, homeopathy, progressive relaxation, guided imagery, acupuncture, acupuncture, relaxation techniques, hypnotherapy, healing touch, movement therapy, pilates, rolfing structural integration, mindfulness, Ayurvedic medicine, traditional Chinese herbs and medicines, naturopathy, essential oils, aromatherapy, Reiki, cranial sacral therapy and applied prayer (as is common in all religions, like Christianity, Hinduism, Buddhism and Judaism) [22]. The Biofield Energy Healing Treatment (The Trivedi Effect®) has been published in numerous peer-reviewed science journals due to its significant impacts in the science fields of biotechnology, genetics, cancer, microbiology, materials science, agriculture, and pharmaceuticals. These publications reported that the Biofield Energy Treatment (The Trivedi Effect®) has the astounding capability to transform the physical, structural, chemical, thermal and behavioral properties of several pharmaceuticals [23-25], nutraceuticals [26, 27], organic compounds [28-30], metals and ceramic in materials science [31-33], and improve the overall productivity of crops [34-36] as well as to modulate the efficacy of the various living cells [37-40]. Although magnesium gluconate exhibits the highest bioavailability and moderate solubility in water in comparison to other magnesium salts, humans still face problems in achieving their daily requirements of magnesium.

**Keywords:** The Trivedi Effect®, Energy of Consciousness, Biofield Energy Healers, Magnesium Gluconate, PXRD, PSD, TGA, DSC
The physical and chemical properties such as particle size, crystalline structure, crystallite size, surface area, etc. of a pharmaceutical have a direct influence on the absorption, dissolution, and bioavailability of the drug [42]. The stability of a solid drug with respect to the atmospheric conditions is very important to the pharmaceutical industry during processing, formulation, storage, and packaging in order to achieve better therapeutic efficacy [43]. Biofield Energy Treatment (The Trivedi Effect®) has been reported to change the particle/crystallite size, specific surface area, chemical and thermal behavior of an atom/ion through the possible mediation of neutrinos [44]. By considering these aspects, the physicochemical, structural, thermal and behavioral properties of the Biofield Energy Treated and the untreated magnesium gluconate were studied using various analytical techniques including powder X-ray diffraction (PXRD), particle size distribution (PSD) analysis, Fourier transform infrared (FT-IR) spectrometry, ultraviolet-visible (UV-vis) spectroscopy, thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC).

2. Materials and Methods

2.1. Chemicals and Reagents

Magnesium gluconate hydrate was procured from Tokyo Chemical Industry Co., Ltd. (TCI), Japan. All other chemicals used in the experiment were of analytical grade available in India.

2.2. Biofield Energy Healing Treatment Strategies

Magnesium gluconate hydrate was one of the components of the new proprietary herbomineral formulation, which was developed by our research team and was used per se as the test compound for the current study. The test compound was divided into two parts, one part of the test compound was treated with the Trivedi Effect® by eighteen renowned Biofield Energy Healers and defined as the Trivedi Effect® Treated magnesium gluconate, while the second part of the test compound did not receive any sort of treatment and defined as untreated or control magnesium gluconate sample. The Trivedi Effect® Treatment was provided by the group of eighteen renowned Biofield Energy Healers, who participated in this study and performed The Trivedi Effect® - Energy of Consciousness Healing Treatment remotely to the test compound. Eleven Biofield Energy Healers were remotely located in the U.S.A., four remotely located in Canada, one each of the Biofield Energy Healer remotely located in Ireland, United Kingdom, and Russia, performed the Trivedi Effect® Treatment remotely to the test compound, while the test compound was located in the research laboratory of GVK Biosciences Pvt. Ltd., Hyderabad, India. This Biofield Treatment was provided for 5 minutes through the Healer’s Unique Energy Transmission process remotely to the test compound, which was kept under laboratory conditions. None of the Biofield Energy Healers in this study visited the laboratory in person, nor had any contact with the compounds. Similarly, the control compound was subjected to “sham” healers for 5 minutes, under the same laboratory conditions. The sham healer did not have any knowledge about the Biofield Energy Treatment. After that, the Biofield Energy Treated and the untreated samples were kept in similar sealed conditions and were characterized thoroughly by PXRD, PSD, FT-IR, UV-visible spectroscopy, TGA, and DSC analysis.

2.3. Characterization

2.3.1. Powder X-ray Diffraction (PXRD) Analysis

The XRD analysis was performed on PANalytical X’pert Pro powder X-ray diffractometer system. The control and Biofield Energy Treated samples were prepared taking 500.15 and 500.18 mg respectively. The X-ray of wavelength 1.54056 Å was used. The data was collected in the form of a chart of the Bragg angle (2θ) vs. intensity, and a detailed table containing information on peak intensity counts, d value (Å), relative intensity (%), full width half maximum (FWHM) (θ°). From the XRD results, the crystallite size (G) was calculated using X’pert data collector and X’pert high score plus processing software. The average size of crystallite (G) was calculated from the Scherrer equation [45]. The method was based on the width of the diffraction patterns obtained in the X-ray reflected the crystalline region. The average size of the crystallite (G) was calculated by using the following equation 1:

\[ G = \frac{k\lambda}{b\cos\theta} \]  

Where, k is the equipment constant (0.5), λ is the X-ray wavelength (0.154 nm); b in radians is the full-width at half of the peaks and θ the corresponding Bragg angle.

Percent change in crystallite size (G) was calculated using the following equation 2:

\[ \% \text{ change in crystallite size} = \left( \frac{G_{\text{treated}} - G_{\text{control}}}{G_{\text{control}}} \right) \times 100 \]  

Where, G and Gt denote the crystallite size of the control and Biofield Energy Treated samples, respectively.

2.3.2. Particle Size Distribution (PSD) Analysis

The average particle size and particle size distribution were analyzed using Malvern Mastersizer 2000, UK, with a detection range from 0.01 µm to 3000 µm. The sample unit was filled with dispersant medium and operated the stirrer at 2500 rpm. Alignment of the optics was done and taken the background measurement. After the background measurement, the sample was added in to the sample unit with constant monitoring of the obscuration. When the obscuration of the sample reached in between 15% and 20%, further addition of the sample stopped. When the obscuration was stable, the measurement was taken twice and the average was taken of the two measurements. The average histogram of the two measurements was recorded. The printout of the average histogram of the two measurements were documented in this study. Along with histogram, the data was presented in a table format which includes particle size (µm).
Also, the values at below 10% level (d_{50}), 50% level (d_{50}), and 90% level (d_{90}) were calculated from the histogram, and the calculations such as surface area (m²/g) were done by using Mastersizer 2000 software. Percent change in particle size (d) for at below 10% level (d_{50}), 50% level (d_{50}), and 90% level (d_{90}) was calculated using following equation 3:

\[
\% \text{ change in particle size} = \frac{d_{\text{Treated}} - d_{\text{Control}}}{d_{\text{Control}}} \times 100 \quad (3)
\]

Where, \(d_{\text{Control}}\) and \(d_{\text{Treated}}\) are the particle size (µm) for at below 10% level (d_{50}), 50% level (d_{50}), and 90% level (d_{90}) of the control and Biofield Energy Treated samples, respectively.

Percent change in surface area (S) was calculated using following equation 4:

\[
\% \text{ change in surface area} = \frac{S_{\text{Treated}} - S_{\text{Control}}}{S_{\text{Control}}} \times 100 \quad (4)
\]

Where, \(S_{\text{Control}}\) and \(S_{\text{Treated}}\) are the surface area of the control and Biofield Energy Treated samples, respectively.

2.3.3. Fourier Transform Infrared (FT-IR) Spectroscopy

The FT-IR spectroscopy of the magnesium gluconate was performed using Spectrum Two (Perkin Elmer, USA) Fourier Transform Infrared Spectrometer with the frequency range of 400-4000 cm⁻¹ by using pressed KBr disk technique.

2.3.4. Ultraviolet-Visible (UV-Vis) Spectroscopy

The UV-Vis spectral analysis was carried out using Shimadzu UV-2450 with UV Probe, Japan. The spectrum was recorded using 1 cm quartz cell with a slit width of 1.0 nm. The wavelength ranges chosen for recording the spectra was 190-800 nm. The absorbance spectra (in the range of 0.2 to 0.9) and absorbance maximum (λ_{max}) were recorded.

2.3.5. Thermogravimetric Analysis (TGA)/ Differential Thermogravimetric (DTG) Analysis

The analysis was performed using Instrument TGA Q50 (TA Instruments, USA) thermo gravimetric analysis at a heating rate of 10°C/min from room temperature i.e. 25°C to 900°C in a nitrogen atmosphere. A total of 9 mg of sample was weighed in a platinum crucible. In TGA, the weight loss for each step was recorded in gram as well as in percent loss with respect to the initial weight. Also, the onset, endset, and peak temperatures for each step were recorded in TGA. In DTG, the onset, endset, peak temperature, integral area of the peak, and change in heat (J/g) of each peak were recorded. Percent change in weight loss (W) was calculated using the following equation 5:

\[
\% \text{ change in weight loss} = \frac{W_{\text{Treated}} - W_{\text{Control}}}{W_{\text{Control}}} \times 100 \quad (5)
\]

Where, \(W_{\text{Control}}\) and \(W_{\text{Treated}}\) are the weight loss of the control and Biofield Energy Treated samples, respectively.

2.3.6. Differential Scanning Calorimetry (DSC) Analysis

The analysis was performed using the DSC Q20 (TA Instruments, USA) Differential Scanning Calorimeter. A total of 3.00 mg of the sample was weighed and sealed in aluminum pans and equilibrated at 25°C and heated up to 450°C at the heating rate of 10°C/min under the nitrogen gas as purge atmosphere with the flow rate of 50 mL/min. The values for onset, endset, peak temperature, peak height (mJ or mW), peak area, and change in heat (J/g) for each peak were recorded. Percent change in melting point (T) was calculated using the following equation 6:

\[
\% \text{ change in melting point} = \frac{T_{\text{Treated}} - T_{\text{Control}}}{T_{\text{Control}}} \times 100 \quad (6)
\]

Where, \(T_{\text{Control}}\) and \(T_{\text{Treated}}\) are the melting point of the control and Biofield Energy Treated samples, respectively.

Percent change in latent heat of fusion (ΔH) was calculated using following equation 7:

\[
\% \text{ change in latent heat of fusion} = \frac{\Delta H_{\text{Treated}} - \Delta H_{\text{Control}}}{\Delta H_{\text{Control}}} \times 100 \quad (7)
\]

Where, \(\Delta H_{\text{Control}}\) and \(\Delta H_{\text{Treated}}\) are the latent heat of fusion of the control and Biofield Energy Treated samples, respectively.

3. Results and Discussions

3.1. Powder X-ray Diffraction (PXRD) Analysis

The PXRD diffractograms showed sharp and intense peaks in the control and Biofield Energy Treated magnesium gluconate and no broadening of the peaks were evident (Figure 1), which suggested that the samples are crystalline in nature. PXRD data such as the Bragg angle (2θ), relative intensity (%), full width half maximum (FWHM) (θ°), and crystallite size (G) for the control and Biofield Energy Treated magnesium gluconate are presented in Table 1. The crystallite size was calculated using Scherrer equation [45]. Table 1 displays the changes of the crystallite size and relative intensities along with other XRD peaks in the Biofield Energy Treated magnesium gluconate compared with the control sample. The most intense peak was observed at 2θ equal to 5.36° and 18.75° in control and Biofield Energy Treated samples, respectively (Figure 1, Table 1). Besides, the relative intensities of other peaks were also altered compared with the control sample.

| Entry No. | Bragg angle (°2θ) | Relative Intensity (%) | FWHM (°2θ) | Crystallite size (G, nm) | % change* |
|-----------|------------------|------------------------|------------|-------------------------|-----------|
|           | Control          | Treated                | Control    | Treated                 | Control   | Treated       |                  |
| 1         | 5.36             | 5.35                   | 100.00     | 87.75                   | 0.1171    | 0.1506        | 37.63            | 29.26          | -22.24        |

Table 1. PXRD data of the control and Biofield Energy Treated magnesium gluconate.
The crystallite size values of the Biofield Energy Treated sample at θ equal to nearly 5.4°, 10.2°, 14.2°, 19.3°, 23.9°, 29.6°, 36.0°, and 40.7° (Table 1, entry 1-3, 7, 9, 11, 12, and 14) were significantly decreased from 14.26% to 39.99% compared with the control sample. Consequently, the crystallite size values of the Biofield Energy Treated sample at 2θ equal to nearly 16.1° and 18.8° (Table 1, entry 4 and 6) were remained unchanged compared with the control sample. The crystallite sizes of the Biofield Energy Treated sample at 2θ equal to nearly 18.2°, 22.7°, 27.7°, and 39.9° (Table 1, entry 5, 8, 10, and 13) were significantly increased from 11.07% to 62.57% compared with the control sample. The average crystallite size was significantly decreased in the Biofield Energy Treated magnesium gluconate by 9.71% as compared to the control sample. The energy influenced by surface area and chemical affinity is the driving factor for dissolution efficiency [48-50]. Kale et al. [51] reported that introduction of the external force leads to transform the fine particles into larger particles. The various reasons to increase the particle size are enhanced the bioavailability of magnesium gluconate. The crystal pattern, size and even polymorphic form of a pharmaceutical play important roles in drug solubility, dissolution and bioavailability. It has been reported in the literature that the alteration in crystal morphology has significant impact on the in vitro dissolution rate, with potential for enhancing the bioavailability [43]. So, it can be concluded that the Biofield Energy Healing Treatment might be a very useful method for enhancing the bioavailability of magnesium gluconate.

### 3.2. Particle Size Distribution (PSD) Analysis

The particle size of both the control and Biofield Energy Treated magnesium gluconate were investigated, and the results are shown in Table 2. The particle size of the Biofield Energy Treated sample at d10, d50, and d90 values was increased significantly by 5.36%, 23.10% and 11.11%, respectively compared with the control sample. The surface area the control and Biofield Energy Treated sample was observed as 0.41 m²/g and 0.37 m²/g, respectively (Table 2). The surface area of the Biofield Energy Treated sample was decreased by 9.76% compared to the control sample.

| Test Item                        | d10 (µm) | d50 (µm) | d90 (µm) | Surface area (m²/g) |
|----------------------------------|----------|----------|----------|---------------------|
| Control                          | 5.97     | 32.95    | 166.68   | 0.41                |
| Biofield Energy Treated          | 6.29     | 40.56    | 185.20   | 0.37                |
| % change<sup>a</sup>             | 5.36     | 23.10    | 11.11    | -9.76               |

<sup>a</sup> denotes the percentage change in the particle size data (d10, d50, and d90) and surface area of the Biofield Energy Treated sample with respect to the control sample.

It has been reported that the changes in the XRD patterns, such as crystallite size and relative intensities, indicated the modification of the crystal morphology as well as the proof of polymorphic transition [46, 47]. As the crystal morphology of the Biofield Energy Treated sample was altered compared with the control sample, the Biofield Energy Treated sample might be a new polymorphic form of magnesium gluconate. The crystal pattern, size and even polymorphic form of a pharmaceutical play important roles in drug solubility, dissolution and bioavailability. The FMHM: Full width at half maximum, <sup>a</sup> denotes the percentage in the crystallite size of the Biofield Energy Treated sample with respect to the control sample.

### Figure 1. X-ray diffractograms of the control and Biofield Energy Treated magnesium gluconate.

The particle size of both the control and Biofield Energy Treated magnesium gluconate were investigated, and the results are shown in Table 2. The particle size of the Biofield Energy Treated sample at d10, d50, and d90 values was increased significantly by 5.36%, 23.10% and 11.11%, respectively compared with the control sample. The surface area the control and Biofield Energy Treated sample was observed as 0.41 m²/g and 0.37 m²/g, respectively (Table 2). The surface area of the Biofield Energy Treated sample was decreased by 9.76% compared to the control sample.

| Test Item                        | d10 (µm) | d50 (µm) | d90 (µm) | Surface area (m²/g) |
|----------------------------------|----------|----------|----------|---------------------|
| Control                          | 5.97     | 32.95    | 166.68   | 0.41                |
| Biofield Energy Treated          | 6.29     | 40.56    | 185.20   | 0.37                |
| % change<sup>a</sup>             | 5.36     | 23.10    | 11.11    | -9.76               |

<sup>a</sup> denotes the percentage change in the particle size data (d10, d50, and d90) and surface area of the Biofield Energy Treated sample with respect to the control sample.
powder flowability, improved product shape and appearance [51]. It is presumed that the Biofield Energy Healing Treatment (i.e. consider as external force) might improve the powder flowability, shape and appearance of magnesium gluconate. PXRD data also supported that the Biofield Energy Healing Treatment could alter the size, shape, and appearance of magnesium gluconate.

3.3. Fourier Transform Infrared (FT-IR) Spectroscopy

The FT-IR spectra of the control and Biofield Energy Treated magnesium gluconate are represented in Figure 2. A broad band with high intensity in the range from 3200 to 3600 cm$^{-1}$ centroid at 3398 cm$^{-1}$ was observed in both spectra of the control and Biofield Energy Treated samples (Figure 2). This peak was attributed to the stretching vibrations of hydroxyl groups originating from the water present in magnesium gluconate. The bands of stretching vibrations of the primary and secondary hydroxyl groups from the gluconate part of the compound appeared in this region. These bands were remained invisible due to the intensive broad band of water [52].

![Figure 2. FT-IR spectra of the control and Biofield Energy Treated magnesium gluconate.](image)

The absorption peaks for the deformation vibration of the hydroxyl groups in the plane $\delta$(OH) and out-of-plane $\gamma$(OH) that indicate the presence of primary and secondary hydroxyl groups were observed at 1433 cm$^{-1}$ and 577 cm$^{-1}$, respectively in the spectra of both the control and Biofield Energy Treated magnesium gluconate. The FT-IR spectra of the control and Biofield Energy Treated magnesium gluconate samples showed C-H stretching at 2933 cm$^{-1}$ and 1380 cm$^{-1}$. A very sharp and intensive band at 1605 cm$^{-1}$ for C=O stretching vibration of a carbonyl group of carboxylate anion was observed in the spectra of both the control and Biofield Energy Treated magnesium gluconate. The band of the C=O stretching vibrations of the primary alcohol group was perceived at 1056 cm$^{-1}$ in the spectra of both the control and Biofield Energy Treated magnesium gluconate. The FT-IR analysis indicated that there was no significant alteration of the characteristic peaks for the functional groups. Hence, it can be concluded that the structure of the magnesium gluconate remained the same in both the Biofield Energy Treated and control samples.

3.4. Ultraviolet-Visible (UV-Vis) Spectroscopy

The UV-vis spectra of both the control and Biofield Energy Treated samples showed that the wavelength for the maximum absorbance at 198 nm ($\lambda_{\text{max}}$) (Figure 3).

![Figure 3. UV-vis spectra of the control and Biofield Energy Treated magnesium gluconate.](image)

The peak at 198 nm showed a minor shift of absorbance maxima from 2.2291 in the control sample to 2.2553 in the Biofield Energy Treated sample. The UV absorbance happens due to the different types of energy transitions from the singlet to the singlet excited state such as $\sigma\rightarrow\sigma^*$, $n\rightarrow\pi^*$, and $\pi\rightarrow\pi^*$. These types of electronic transitions are occurred when the difference in energy between the lowest unoccupied molecular orbital (LUMO) and the highest occupied molecular orbital (HOMO) is significantly higher than the activation energy of the compound [53]. As there was no significant alternation in the $\lambda_{\text{max}}$ of the Biofield Energy Treated sample compared with the control, it is inferred that the structural configuration or activation energy of the Biofield Energy Treated sample was not different from the control sample.

3.5. Thermogravimetric Analysis (TGA)/ Differential Thermogravimetric (DTG) Analysis

The TGA thermograms of both the control and Biofield Energy Treated samples exhibited three steps of thermal degradation (Figures 4 and Table 3). The control sample lost their weight by 2.85%, 37.91%, and 42.44% in the 1st, 2nd and 3rd steps of degradation, respectively (Table 3). Similarly, the Biofield Energy Treated sample was lost weight by 3.75%, 35.04%, and 44.96% in the 1st, 2nd and 3rd steps of degradation, respectively (Table 3). The weight loss of the Biofield Energy Treated sample in the first and third steps of degradation was increased by 31.58% and 5.94%, respectively, whereas in the second step of degradation, the weight loss was decreased by 7.57% compared with the control sample. The overall weight loss was 83.20% and 83.75% in the control and Biofield Energy Treated samples, respectively from their original total weight during this process (Figure 4). The total weight loss was slightly increased by 0.66% in the Biofield Energy Treated sample compared with the control sample. The DTG thermograms of the control and Biofield Energy Treated samples disclosed
maximum temperature ($T_{\text{max}}$) at 244.81°C and 243.71°C, respectively (Figure 5). The onset degradation temperature was at 232.38°C for control, and 232.45°C for the Biofield Energy Treated sample. The end-set degradation temperature was observed at 272.12°C for the control sample and 276.56°C for the Biofield Energy Treated sample, respectively. The DTG analysis indicated that the decomposition temperature of the Biofield Energy Treated magnesium gluconate was altered compared with the control sample. Overall, TGA/DTG revealed that the weight loss of the Biofield Energy Treated magnesium gluconate and maximum temperature during the thermal degradation process were changed compared with the control sample.

### Table 3. Thermal degradation steps of the control and Biofield Energy Treated magnesium gluconate.

| S. No. | Temperature (°C) | % Weight loss | % Change<br>a |
|--------|-----------------|--------------|----------------|
|        | Control         | Treated      | Control        | Treated        |          |
| 1st step of degradation | 151.63 | 155.49 | 2.85 | 3.75 | 31.58 |
| 2nd step of degradation  | 260.56 | 252.06 | 37.91 | 35.04 | -7.57 |
| 3rd step of degradation  | 896.09 | 895.61 | 42.44 | 44.96 | 5.94 |
| Total | 83.20 | 83.75 | 0.66 |

*a* denotes the percentage change in the weight loss of the Biofield Energy Treated sample with respect to the control sample.

![Figure 4. TGA thermograms of the control and Biofield Energy Treated magnesium gluconate.](image4.png)

![Figure 5. DTG thermograms of the control and Biofield Energy Treated magnesium gluconate.](image5.png)

### 3.6. Differential Scanning Calorimetry (DSC) Analysis

The DSC thermograms of the control and Biofield Energy Treated samples of magnesium gluconate are shown in Figure 6. The melting point of the Biofield Energy Treated sample (170.29°C) was decreased slightly by 0.31% compared with the control sample (169.76°C). The latent heat of fusion ($\Delta H$) of the control and Biofield Energy Treated samples were 298.8 J/g and 311.3 J/g, respectively. The latent heat of fusion ($\Delta H$) was increased by 4.18% in the Biofield Energy Treated sample compared with the control sample. The data indicated that the Biofield Energy Treated magnesium gluconate needs more energy in the form of latent heat of fusion in order to undergo the process of melting after the Biofield Energy Treatment. It is presumed that the Biofield Energy Treatment might induce the intermolecular force in the Biofield Energy Treated magnesium gluconate, which possibly induced the heat change. It is also hypothesized that the Biofield Energy Treatment may cause emission of less energy during the phase transition from solid state to the liquid state, and that might be lead to increase in $\Delta H$ in the Biofield Energy Treated sample compared with the control sample.

### Table 4. The latent heat of fusion (J/G) and melting point (°C) values of the control and Biofield Energy magnesium gluconate.

| Sample                  | Latent heat of fusion (\(\Delta H\)) J/g | Onset melting temperature \(T_{\text{onset}}\) °C | Peak melting temperature \(T_{\text{peak}}\) °C | Endset melting temperature \(T_{\text{endset}}\) °C |
|-------------------------|----------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Control                 | 298.80                                 | 159.45                                      | 170.29                                      | 188.06                                      |
| Biofield Energy Treated | 311.30                                 | 157.40                                      | 169.76                                      | 188.06                                      |
| % Change\textsuperscript{a} | 4.18                                   | -1.29                                       | -0.31                                       | 0.00                                        |

\(T_{\text{onset}}\): Onset melting temperature, \(T_{\text{peak}}\): Peak melting temperature, \(T_{\text{endset}}\): Endset melting temperature, $\Delta H$: Latent heat of fusion, \textsuperscript{a} denotes the percentage change of the Biofield Energy Treated sample with respect to the control sample.
4. Conclusions

The current study anticipated the notable impact of The Trivedi Effect® - Energy of Consciousness Healing Treatment on the physicochemical, thermal, structural, and behavioral properties of magnesium gluconate. The PXRD analysis exhibited that the crystallite size of the Trivedi Effect® Energy Treated sample was significantly altered from -39.99% to 62.57% compared with the control sample. The average crystallite size of the Biofield Energy Treated magnesium gluconate was decreased in the by 9.70% compared with the control sample. This result indicated the significant alteration of the crystal morphology of the treated sample compared with the control sample. Particle size of the treated sample at $d_{10}$, $d_{50}$, and $d_{90}$ value was significantly increased by 5.36%, 23.10% and 11.11%, respectively compared with the control sample. The surface area of the treated sample was significantly decreased by 9.76% compared to the control sample. The TGA data revealed three steps of degradation process and the weight loss of the first and third steps of degradation in the treated sample was increased by 31.58% and 5.94%, respectively, whereas in the second step of degradation, the weight loss was decreased by 7.57% compared with the control sample. The melting point of the control and treated samples were at 170.29°C and 169.76°C, respectively. Consequently, the latent heat of fusion of the treated sample was increased by 4.18% compared with the control sample. Therefore, the treated magnesium gluconate would be a new polymorphic form, which might have the better powder flowability and long-term storage stability compared with the control sample. Thus, The Trivedi Effect® - Energy of Consciousness Healing Treatment, could be a useful approach in the design of better nutraceutical and/or pharmaceutical formulations that can offer significant therapeutic responses against various diseases such as diabetes mellitus, allergies and septic shock; stress-related disorders like sleep disorder, insomnia, anxiety, depression, Attention Deficit Disorder (ADD), Attention Deficit Hyperactive Disorder (ADHD), mental restlessness (mind chattering), brain frog, low libido, impotency, lack of motivation, mood swings, fear of the future, confusion, migraines, headaches, forgetfulness, overwhelm, loneliness, worthlessness, indecisiveness, frustration, irritability, chronic fatigue, obsessive/compulsive behavior and panic attacks; inflammatory diseases and immunological disorders like Lupus, Systemic Lupus Erythematosus, Hashimoto Thyroiditis, Type 1 Diabetes, Asthma, Chronic peptic ulcers, Tuberculosis, Hepatitis, Chronic active hepatitis, Celiac Disease (gluten-sensitive enteropathy), Addison Disease, Crohn's disease, Graves’ Disease, Pernicious and Aplastic Anemia, Sjogren Syndrome, Irritable Bowel Syndrome (IBS), Multiple Sclerosis, Rheumatoid arthritis, Chronic periodontitis, Ulcerative colitis, Chronic sinusitis, Myasthenia Gravis, Atherosclerosis, Vasculitis, Dermatitis, Diverticulitis, Rheumatoid Arthritis, Reactive Arthritis, Alopecia Areata, Psoriasis, Scleroderma, Fibromyalgia, Chronic Fatigue Syndrome and Vitiligo; aging-related diseases like cardiovascular disease, arthritis, cancer, Alzheimer’s disease, dementia, cataacts, osteoporosis, diabetes, hypertension, glaucoma, hearing loss, Parkinson’s Disease, Huntington’s Disease, Prion Disease, Motor Neurone Disease, Spinocerebellar Ataxia, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Friedreich’s Ataxia and Lewy Body Disease; chronic infections and much more.

Abbreviations

DSC: Differential scanning calorimetry, FT-IR: Fourier transform infrared spectroscopy, FWHM: Full width half maximum, G: Crystallite size, HOMO: Highest energy occupied molecular orbital, LUMO: Lowest energy unoccupied molecular orbital, TGA: Thermal gravimetric analysis, $T_{\text{onset}}$: Onset melting temperature, $T_{\text{peak}}$: Peak melting temperature, $T_{\text{endset}}$: Endset melting temperature, $\Delta H$: Latent heat of fusion, UV-vis: Ultraviolet-visible spectroscopy, PSD: Particle size distribution; PXRD: Powder X-ray diffraction.

Acknowledgements

The authors are grateful to GVK Biosciences Pvt. Ltd., Trivedi Science, Trivedi Global, Inc. and Trivedi Master Wellness for their assistance and support during this work.

References

[1] Swaminathan R (2003) Magnesium metabolism and its disorders. Clin Biochem Rev 24: 47-66.
NMR spectroscopy in biological and medicinal inorganic chemistry. Coord Chem Rev 252: 2239-2277.

Ronconi L, Sadler PJ (2008) Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry. Coord Chem Rev 252: 2239-2277.

Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Latiyal O, Jana S (2015) Potential impact of biofield treatment on atomic and physical characteristics of magnesium. Vitam Miner 3: 129.

Guerrera MP, Volpe SL, Mao JJ (2009) Therapeutic uses of magnesium. Am Fam Physician 80: 157-162.

Gums JG (2004) Magnesium in cardiovascular and other disorders. Am J Health Syst Pharm 61: 1569-1576.

Purvis JR, Movahed A (1992) Magnesium disorders and cardiovascular diseases. Clin Cardiol 5: 556-568.

Sales CH, Pedrosa Lde F (2006) Magnesium and diabetes mellitus. Their relation. Clin Nutr 25: 554-562.

Nageris BI, Ulanovski D, Attias J (2004) Magnesium bioavailability from ten organic and inorganic Mg salts in Mg-deficient rats. Magmas Res 18: 215-223.
[35] Nayak G, Altekar N (2015) Effect of a biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.

[36] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Impact of biofield energy treatment on soil fertility. Earth Sciences 4: 275-279.

[37] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Antimicrobial sensitivity, biochemical characteristics and biotyping of Staphylococcus saprophyticus: An impact of biofield energy treatment. J Women’s Health Care 4: 271.

[38] Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M, Jana S (2015) Use of energy healing medicine against Escherichia coli for antimicrobial susceptibility, biochemical reaction and biotyping. American Journal of Bioscience and Bioengineering 3: 99-105.

[39] Trivedi MK, Branton A, Trivedi D, Shettigar H, Nayak G, Mondal SC, Jana S (2015) Phenotyping and genotyping characterization of Proteus vulgaris after biofield treatment. International Journal of Genetics and Genomics 3: 66-73.

[40] Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) In vitro evaluation of biofield treatment on cancer biomarkers involved in endometrial and prostate cancer cell lines. J Cancer Sci Ther 7: 253-257.

[41] Ranade VV, Somberg JC (2001) Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther 8: 345-357.

[42] Chereson R (2009) Bioavailability, bioequivalence, and drug selection. In: Makoid CM, Vuchetich PJ, Banakar UV (eds) Basic pharmacokinetics (1st Edn) Pharmaceutical Press, London.

[43] Blagden N, de Matas M, Gavan PT, York P (2007) Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59: 617-630.

[44] Trivedi MK, Mohan TRR (2016) Biofield energy signals, energy transmission and neutrinos. American Journal of Modern Physics 5: 172-176.

[45] Langford JI, Wilson AJC (1978) Scherrer after sixty years: A survey and some new results in the determination of crystallite size. J Appl Cryst 11: 102-113.

[46] Inoue M, Hirasewa I (2013) The relationship between crystal morphology and XRD peak intensity on CaSO₄·2H₂O. J Crystal Growth 380: 169-175.

[47] Raza K, Kumar P, Ratam S, Malik R, Arora S (2014) Polymorphism: The phenomenon affecting the performance of drugs. SOJ Pharm Pharm Sci 1: 10.

[48] http://www.dissolution.com/ddg/showthread.php?2366-Surface-Area-vs-Particle-Size

[49] Mosharrof M, Nyström C (1995) The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm 122: 35-47.

[50] Martin AN, Patrick JS (2006) Martin's physical pharmacy and pharmaceutical sciences: Physical chemical and biopharmaceutical principles in the pharmaceutical sciences. Phila: Lippincott Williams and Wilkins.

[51] Kale VV, Gadakar S, Ittadwar AM (2011) Particle size enlargement: Making and understanding of the behavior of powder (particle) system. Syst Rev Pharm 2: 79.

[52] Nikolić VD, Ilić DP, Nikolić, LB, Stanojević, LP, Cakić MD, Tačić AD, Ilić-Stojanović SS (2014) The synthesis and characterization of iron (II) gluconate. Advanced technologies 3: 16-24.

[53] Hesse M, Meier H, Zeeh B (1997) Spectroscopic methods in organic chemistry, Georg Thieme Verlag Stuttgart, New York.